Last reviewed · How we verify
NCT03915002: InLi
Integrated Approaches for Identifying Molecular Targets in Liver Disease
trial in Alcoholic Liver Disease in 155 participants. Completed in 12 April 2023.
12 April 2023
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 155 |
| Start date | 13 June 2019 |
| Primary completion | 12 April 2023 |
| Estimated completion | 12 April 2023 |
| Sites | 1 location across United States |
Conditions studied
- Alcoholic Liver Disease — all drugs for Alcoholic Liver Disease →
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
- Steatohepatitis, Nonalcoholic — all drugs for Steatohepatitis, Nonalcoholic →
- Steatohepatitis — all drugs for Steatohepatitis →
Sponsor
University of Pittsburgh
Who can join
Adults 18 to 75, any sex, with Alcoholic Liver Disease or Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To provide a framework for successful clinical trials testing novel targets for therapy in liver disease. To identify molecular and cellular drivers of liver disease to provide a molecular classification and study the determinants or key drivers of disease progression. Consecutive patients admitted with steatohepatitis (alcoholic or non-alcoholic) will be enrolled in this study where liver tissue, blood and stool will be collected to discover and validate factors associated with diagnosis, severity, histological characteristics, development of decompensations, progression of disease and survival.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants.
Sharma P, Nandave M, Nandave D, Yadav S, et al · · 2023 · cited 20× · PMID 38074830 -
Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches.
Zaiou M, Joubert O. · · 2025 · cited 2× · PMID 40427561 · DOI 10.3390/biom15050669
Verify or expand the search:
- PubMed search for NCT03915002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcoholic Liver Disease
Currently open trials in the same condition.
- NCT06307964 — Intra-Hepatic Microbiota in Alcoholic Hepatitis · recruiting
- NCT05855031 — The Liver Care Trial · NA · recruiting
- NCT05895890 — French National MICMAF Cohort · recruiting
- NCT05007470 — Alcoholic Liver Disease and the Gut Microbiome · NA · active not recruiting
- NCT04858412 — Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19 · NA · recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03915002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing